Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552911 | 0.85 | KDM4E (0.55) | KDM4EPOLBGAAMAPTALDH1A1 | |
| SCHEMBL1553837 | 0.84 | MAPT (0.66) | KDM4EMAPTALDH1A1HSD17B10HPGD | |
| SCHEMBL856059 | 0.83 | MAPT (0.59) | KDM4EPOLBGAAMAPTALDH1A1 | |
| SCHEMBL7405207 | 0.81 | ALDH1A1 (0.53) | KDM4EPOLBGAAMAPTALDH1A1 | |
| SCHEMBL12867382 | 0.81 | GAA (0.58) | KDM4EGAAMAPTALDH1A1HSD17B10 | |
| SCHEMBL27275816 | 0.80 | GAA (0.51) | KDM4EPOLBGAAMAPTALDH1A1 | |
| SCHEMBL1434290 | 0.80 | MAPT (0.71) | KDM4EPOLBGAAMAPTALDH1A1 | |
| SCHEMBL28299854 | 0.79 | HMGCR (0.51) | KDM4EMAPTALDH1A1HSD17B10HPGD | |
| SCHEMBL13959837 | 0.79 | GAA (0.46) | KDM4EGAAMAPTALDH1A1HSD17B10 | |
| SCHEMBL10542808 | 0.79 | MAPT (0.46) | KDM4EPOLBGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934307-B1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LTD (GB) | 2011-04-27 | — | — | EP | disclosed |
| EP-2223920-A2 | Substituted azabicyclic compounds | Aventis Pharma Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7329675-B2 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20050038069-A1 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2005-02-17 | — | — | US | disclosed |
| US-6800645-B1 | INHIBIT PRODUCTION OR PHYSIOLOGICAL EFFECTS OF TNF, INHIBIT CYCLIC AMP PHOSPHODIESTERASE | AVENTIS PHARMA LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20020173527-A1 | Substituted azabicyclic compounds | ASTLES PETER CHARLES (GB) | 2002-11-21 | — | — | US | disclosed |
| US-6303600-B1 | USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY | RHONE-POULENC RORER LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173527-A1 | Substituted azabicyclic compounds | CBR1, NOX1, POR | KDM4E 3056/4885POLB 1006/4885GAA 2226/4885 |
| US-20050038069-A1 | Substituted azabicyclic compounds | NR2C2, NR3C1, NR3C2 | KDM4E 2408/4885POLB 2680/4885GAA 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.